TipRanks

Notifications

Tag: NBIX

Total 266 Posts

JPMorgan העלו את מחיר היעד שלהם עבור Neurocrine מ-148 ליש”ט ל-158 ליש”ט וממשיכים להמליץ על רכישת המניה

האנליסט חוזה כי תוצאות מניסוי שלב 2 של NBI-1117568 לטיפול בסכיזופרניה יהיו זמינות במחצית השנייה של 2024. החברה מגדירה הצלחה כשיפור של 10-13 נקודות לעומת פלצבו בסולם PANSS, המודד תסמיני

Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Arcellx Inc (ACLX) and Exact Sciences (EXAS)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Neurocrine (NBIXResearch Report), Arcellx Inc (ACLXResearch Report) and Exact Sciences (EXASResearch Report) with bullish sentiments.

Neurocrine (NBIX)

In a report issued on March 13, Brian Skorney from Robert W. Baird maintained a Buy rating on Neurocrine, with a price target of $157.00. The company’s shares closed last Thursday at $139.16, close to its 52-week high of $143.35.

According to TipRanks.com, Skorney is a 4-star analyst with an average return of 4.0% and a 46.8% success rate. Skorney covers the Healthcare sector, focusing on stocks such as Crinetics Pharmaceuticals, Enanta Pharmaceuticals, and Vertex Pharmaceuticals.

Currently, the analyst consensus on Neurocrine is a Moderate Buy with an average price target of $150.33, representing a 6.0% upside. In a report issued on March 1, Jefferies also maintained a Buy rating on the stock with a $161.00 price target.

See the top stocks recommended by analysts >>

Arcellx Inc (ACLX)

In a report issued on March 13, Jack Allen from Robert W. Baird maintained a Buy rating on Arcellx Inc, with a price target of $77.00. The company’s shares closed last Thursday at $69.57, close to its 52-week high of $75.10.

According to TipRanks.com, Allen is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -8.7% and a 37.7% success rate. Allen covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, BioMarin Pharmaceutical, and Crispr Therapeutics AG.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Arcellx Inc with a $79.55 average price target, which is a 13.4% upside from current levels. In a report issued on March 7, Morgan Stanley also initiated coverage with a Buy rating on the stock with a $81.00 price target.

Exact Sciences (EXAS)

In a report issued on March 13, Catherine Ramsey Schulte from Robert W. Baird assigned a Buy rating to Exact Sciences, with a price target of $82.00. The company’s shares closed last Thursday at $58.53, close to its 52-week low of $56.05.

According to TipRanks.com, Schulte is a 5-star analyst with an average return of 11.0% and a 53.3% success rate. Schulte covers the Healthcare sector, focusing on stocks such as Maravai Lifesciences Holdings, Castle Biosciences, and Twist Bioscience.

Exact Sciences has an analyst consensus of Strong Buy, with a price target consensus of $91.60.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on NBIX: